San Diego, California • Velocity Clinical Research
Phone: (619) 567-1550
Nonalcoholic steatohepatitis (NASH) is the more serious form of metabolic dysfunction-associated steatotic liver disease (MASLD) which causes the liver to swell and become damaged. Fibrosis of the liver is a driving factor in the progression from NASH to end stage liver disease. Not all patients with steatosis will progress to NASH and there are currently no clear criteria to identify these patients. There are currently no approved medications for the treatment of NASH.
Velocity is conducting a study for an investigational NASH medication.
For more information, complete the form on this page. After you submit your information, a Velocity enrollment specialist will call you to talk about the study. There is no obligation to participate — you can decide if the study is right for you.
©2023 Velocity Clinical Research | All Rights Reserved | Privacy Policy